Please login to the form below

Not currently logged in
Email:
Password:

Myalept

This page shows the latest Myalept news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

For example, Amgen's Blincyto (blinatumomab) for a rare form of leukaemia has been priced at $178, 000 a year, while AZ's Myalept (metreleptin) for the ultra-rare metabolic disorder

Latest news

  • Nexium windfall lifts AZ in third quarter Nexium windfall lifts AZ in third quarter

    Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals. ... The latter will pay $325m upfront to acquire the global rights to Myalept, subject to an existing distributor

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    Epanova gets green light to reduce high levels of fat in the blood

  • AZ gets limited approval for metreleptin in US AZ gets limited approval for metreleptin in US

    First FDA-backed treatment for rare disease lipodystrophy. AstraZeneca's Myalept has become the first approved treatment for the rare disease lipodystrophy after getting a green light from the FDA. ... Myalept will be "a much-needed treatment option for

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics